Physician profile
Han Zhang
NPI 1598723702
$6,556.71
in general payments reported to CMS, 2019-2025
36 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $768 · 2021: $1,170 · 2022: $398 · 2023: $853 · 2024: $885 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $999.08 | 2019-2025 | |
| Amgen INC. | $776.52 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.65 | 2019-2024 | Ofev, Jardiance |
| Sanofi Pasteur INC. | $434.39 | 2019-2025 | |
| Amarin Pharma, INC. | $405.08 | 2019-2023 | |
| Lilly USA, LLC | $403.05 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $348.20 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $329.43 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $323.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $299.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $190.12 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Agios Pharmaceuticals, INC. | $165.63 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $158.50 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.07 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $121.23 | 2020-2024 | Linzess |
| Abbvie INC. | $90.32 | 2021-2024 | Linzess |
| Genentech USA, INC. | $83.37 | 2019-2021 | |
| Novo Nordisk INC | $70.26 | 2019-2025 | |
| Optinose US, INC. | $61.82 | 2019 | |
| Ibsa Pharma INC. | $56.13 | 2021 | |
| Aimmune Therapeutics, INC. | $45.31 | 2023-2025 | Vowst |
| Kowa Pharmaceuticals America, INC. | $45.25 | 2024-2025 | Zoryve |
| Aytu Biopharma, INC. | $44.31 | 2024 | Karbinal |
| Xeris Pharmaceuticals, INC. | $37.50 | 2023-2024 | Keveyis |
| Hikma Pharmaceuticals USA | $32.46 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.22 | 2019 | |
| Esperion Therapeutics, INC. | $25.00 | 2025 | Nexletol |
| Alexion Pharmaceuticals, INC. | $25.00 | 2021 | |
| Eisai INC. | $20.48 | 2024 | |
| Radius Health, INC. | $20.00 | 2020 | |
| Meridian Bioscience INC. | $19.92 | 2019 | |
| Modernatx, INC. | $17.31 | 2025 | Mresvia |
| Allergan, INC. | $16.82 | 2020 | |
| Hologic Sales and Service, LLC | $16.13 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.